25503-64-4

Upstream product

• 56346-57-7 (4-fluorophenyl)-piperidin-4-ylmethanone 
• 108-20-3 di-isopropyl ether 
• 627-18-9 1-bromo-3-propanol 
• 142221-79-2 4-(4-fluorobenzoyl)piperidine hydrobromide 

Downstream Products

• 132332-45-7 2-{3-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-propyl}-6,7-dihydro-5H-pyrrolo[1,2-c]pyrimidine-1,3-dione 
• 132332-29-7 3-{3-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-propyl}-5-phenyl-1H-pyrimidine-2,4-dione 
• 133364-67-7 3-[3-[4-(4-Fluorobenzoyl)piperidin-1-yl)propyl]-6,7,8,9-tetrahydro-2H-pyrido[1,2-a]-1,3,5-triazine-2,4(3H)-dione 
• 62030-92-6 [1-(3-chloropropyl)-4-piperidinyl](4-fluorophenyl)methanone 

Relevant academic research and scientific papers

Subtype-selective NMDA receptor ligands and the use thereof

The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neuro-degenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

1,5-Disubstituted-1,2-dihydro-2H-1,4-benzodiazepin-2-ones

1,5-Disubstituted-1,2-dihydro-2H-1,4-benzodiazepin-2-ones of the formula STR1 wherein R is hydrogen or fluoro, R1 is hydrogen, fluoro chloro, bromo or trifluoromethyl, and n is 2 to 4, having anticonvulsant activity and useful as anti-anxiety agents, are disclosed.

(1-(3-(Phenothiazin-10-yl)propyl)-4-piperidinyl)phenylmethanones, a novel class of long-acting neuroleptic agents.

In previous studies the phenyl-4-piperidinylmethanone moiety was shown to be a neuroleptic pharmacophore. A short series of [1-[3-(phenothiazin-10-yl)propyl]-4-piperidinyl]phenylmethanones was prepared and tested for neuroleptic activity using the blockade of d-amphetamine lethality in aggregated mice and suppression of conditioned avoidance behavior as the end points. Most compounds were shown to be potent neuroleptic agents and two were found to possess a long duration of action.